BHT-3009 demonstrated promising effects on radiological disease activity in active MS patients in a phase 1/2 study, a reduction of MBP-specific CD4+ T cells with a Th1 phenotype in peripheral blood and a decrease of myelin-specific auto-antibody titers in CSF (45). This evidence concerns the gene CD4 and myeloid sarcoma.